Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer

Conclusion: This first-in-human study demonstrates that 99mTc-labeled anti–PD-L1-single-domain antibody SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2 h when the T:BP ratio correlates with PD-L1 immunohistochemistry results.

Source: Journal of Nuclear Medicine - September 2, 2019 Category: Nuclear Medicine Authors: Xing, Y., Chand, G., Liu, C., Cook, G. J. R., ODoherty, J., Zhao, L., Wong, N. C. L., Meszaros, L. K., Ting, H. H., Zhao, J. Tags: Clinical Source Type: research